ENTITY

Cadrenal Therapeutics (CVKD US)

14
Analysis
Health Care • United States
Cadrenal Therapeutics, Inc. operates as a biotech company. The Company focuses on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation. Cadrenal Therapeutics serves customers worldwide.
more
Exchange Announcement • 09 Oct 2026 05:07

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Exchange Announcement • 07 Oct 2026 21:23

Current Report (Form 8-K | Period ending 2026-10-07)

Exchange Announcement • 30 Sep 2026 04:05

Current Report (Form 8-K | Period ending 2026-09-24)

Exchange Announcement • 31 Aug 2026 20:29

Current Report (Form 8-K | Period ending 2026-08-31)

Exchange Announcement • 14 Aug 2026 04:31

Quarterly Report (Form 10-Q | Period ending 2026-06-30)

x